Friday, December 14, 2012
Robert Deans Exec VP Regenerative Medicine, Athersys, Inc and ReGenesys, BVBA
The impact of stem cell biology on medicine is likely comparable to the unraveling of the human genome and recombinant DNA technology in the context of envisioned future therapies. This vision brings many challenges outside of the immediate scientific development hurdles. The core science behind adult and pluripotent stem cell therapies and current clinical development status will be discussed, including the impact of global regulatory policies on models of practice and medical tourism. The bioprocessing industry is adapting to meet scale requirements in manufacturing and personalized medicine paradigms for practice. iPS technology is driving genome science and epigenetic technology to enable personalized diagnostics and personalized treatment, leading to a paradigm where post-natal tissue collection and genome analysis will determine individual healthcare futures. Bringing regenerative medicine to the standard of care is now facing its biggest hurdle with reimbursement expectations confronting ceilings in our healthcare system. Patient and industry advocacy organizations are building community engagement to attract development capital and construct economically sound business models for this future.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?